JNK

c-Jun N-terminal kinase



JNKs (c-Jun N-terminal kinases) belong to the mitogen-activated protein kinase family, and are responsive to stress stimuli, such as cytokines,ultraviolet irradiation, heat shock, and osmotic shock. JNKs play a role in T cell differentiation and the cellular apoptosis pathway. Activation occurs through a dual phosphorylation of threonine (Thr) and tyrosine (Tyr) residues within a Thr-Pro-Tyr motif located in kinase subdomain VIII. Activation is carried out by two MAP kinases, MKK4 and MKK7 and JNK can be inactivated by Ser/Thr and Tyr protein phosphatases. Downstream molecules that are activated by JNK include c-Jun, ATF2, ELK1, SMAD4, p53 and HSF1. JNKs can associate with scaffold proteins JNK interacting proteins as well as their upstream kinases JNKK1 and JNKK2 following their activation. JNK activity regulates several important cellular functions including cell growth, differentiation, survival and apoptosis.

JNK Inhibitors & Modulators

Anisomycin

(Flagecidin; Wuningmeisu C)

Cat. No.: HY-18982

Bioactivity: Anisomycin is a potent **protein synthesis** inhibitor which interferes with protein and **DNA synthesis** by inhibiting peptidyl transferase or the 80S ribosome system. Anisomycin is a JNK activator, which increases phospho-JNK.

Purity: 98.20%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



AS601245

Cat. No.: HY-11010

Bioactivity: AS601245 is a **JNK** Inhibitor with **IC_{50}**s of 150, 220, and 70 nM for three JNK human isoforms (**hJNK1**, **hJNK2**, and **hJNK3**), respectively.

Purity: 98.32%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg



Astragaloside IV

Cat. No.: HY-N0431

Bioactivity: Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of **ERK1/2** and **JNK**, and downregulates matrix metalloproteases **(MMP)-2, (MMP)-9** in MDA-MB-231 breast cancer cells.

Purity: 99.15%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Bentamapimod

(AS 602801)

Cat. No.: HY-14761

Bioactivity: Bentamapimod (AS 602801) is an ATP-competitive **JNK** inhibitor with **IC_{50}** of 80 nM, 90 nM, and 230 nM for **JNK1**, **JNK2**, and **JNK3**, respectively.

Purity: 98.60%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



BI-78D3

Cat. No.: HY-10366

Bioactivity: BI-78D3 functions as a substrate competitive inhibitor of **JNK**, inhibit the JNK kinase activity (**IC_{50}**=280 nM).

Purity: 99.64%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



CC-401

Cat. No.: HY-13022A

Bioactivity: CC-401 is a potent inhibitor of all three forms of **JNK** with **K_i** of 25 to 50 nM.

Purity: >98%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg



CC-401 hydrochloride

(CC401 HCl)

Cat. No.: HY-13022

Bioactivity: CC-401 hydrochloride is a potent inhibitor of all three forms of **JNK** with **K_i** of 25 to 50 nM.

Purity: 99.45%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



D-JNKI-1

(AM-111; XG-102)

Cat. No.: HY-P0069

Bioactivity: D-JNKI-1 is a highly potent and cell-permeable peptide inhibitor of **JNK**.

Purity: 95.83%
Clinical Data: Phase 3
Size: 1 mg, 5 mg, 10 mg, 50 mg

DB07268

Cat. No.: HY-15737

Bioactivity: DB07268 is a potent and selective **JNK1** inhibitor with an **IC_{50}** value of 9 nM.

Purity: 99.49%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Ginsenoside Re

(Ginsenoside B2; Panaxoside Re; Sanchinoside Re)

Cat. No.: HY-N0044

Bioactivity: Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the **β-amyloid** protein (**Aβ**). Ginsenoside Re plays a role in antiinflammation through inhibition of **JNK** and **NF-κB**.

Purity: 98.04%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

IQ-1S free acid

Cat. No.: HY-100233

Bioactivity: IQ-1S free acid is a prospective inhibitor of **NF-κB**/activating protein 1 (**AP-1**) activity with an **IC_{50}** of 2.3±0.41 μM. IQ-1S free acid has binding affinity (K_d values) in the nanomolar range for all three **JNK**s with **K_d**s of 100 nM, 240 nM, ...

Purity: 98.58%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Isovitexin

(Saponaretin; Homovitexin)

Cat. No.: HY-N0773

Bioactivity: Isovitexin is a flavonoid isolated from rice hulls of Oryza sativa, possesses anti-inflammatory and anti-oxidant activities; Isovitexin acts like a **JNK1/2** inhibitor and inhibits the activation of **NF-κB**.

Purity: 98.94%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



JNK Inhibitor VIII

(TCS JNK 6o)

Cat. No.: HY-107598

Bioactivity: JNK Inhibitor VIII (TCS JNK 6o) is a **c-Jun N-terminal kinases (JNK-1, -2, and -3)** inhibitor with **K_i** values of 2 nM, 4 nM, 52 nM, respectively [1].

Purity: 99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg



JNK-IN-7

(JNK inhibitor)

Cat. No.: HY-15617

Bioactivity: JNK-IN-7 is a potent **JNK** inhibitor with **IC_{50}** of 1.5, 2 and 0.7 nM for **JNK1**, **JNK2** and **JNK3**, respectively.

Purity: 98.05%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



JNK-IN-8

Cat. No.: HY-13319

Bioactivity: JNK-IN-8 is a potent **JNK** inhibitor with **IC_{50}**s of 4.7 nM, 18.7 nM, and 1 nM for **JNK1**, **JNK2**, and **JNK3**, respectively.

Purity: 99.38%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Juglanin

Cat. No.: HY-N3442

Bioactivity: Juglanin is a **JNK** activator.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg



L-JNKI-1

Cat. No.: HY-P0069A

Bioactivity: L-JNKI-1 is a cell-permeable peptide inhibitor specific for **JNK**.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

Loureirin B

Cat. No.: HY-N1504

Bioactivity: Loureirin B, a flavonoid extracted from **Dracaena cochinchinensis**, is an inhibitor of plasminogen activator inhibitor-1 **(PAI-1)**, with an IC_{50} of 26.10μM; Loureirin B also inhibits **K_{ATP}**, the phosphorylation of **ERK** and **JNK**

Purity: 99.99%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg



Rutin hydrate

(Rutoside hydrate; Quercetin 3-O-rutinoside hydrate)

Cat. No.: HY-N0148A

Bioactivity: Rutin hydrate is a flavonol glycoside, able to cross the blood-brain barrier, and acts by inhibiting **JNK** and **ERK1/2** activation and activating **mTOR** signalling.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 g, 10 g



SP600125

Cat. No.: HY-12041

Bioactivity: SP600125 is a reversible and ATP-competitive **JNK** inhibitor with **IC_{50}**s of 40, 40 and 90 nM for **JNK1**, **JNK2** and **JNK3**, respectively.

Purity: 98.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



SR-3306

Cat. No.: HY-12829

Bioactivity: SR-3306 is a selective, potent, highly brain penetrant **JNK** inhibitor.

Purity: 99.00%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Tanzisertib

(CC-930)

Cat. No.: HY-15495

Bioactivity: Tanzisertib (CC-930) is a potent **JNK1/2/3** inhibitor with **IC_{50}**s of 61/7/6 nM, respectively.

Purity: 99.92%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



TCS JNK 5a

(JNK Inhibitor IX)

Cat. No.: HY-15881

Bioactivity: TCS JNK 5a is a potent **JNK3** inhibitor with a **pIC_{50}** of 6.7.
TCS JNK 5a also inhibits **JNK2** with a **pIC_{50}** of 6.5.

Purity: 98.91%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Tomatidine

Cat. No.: HY-N2149

Bioactivity: Tomatidine acts as an anti-inflammatory agent by blocking **NF-κB** and **JNK** signaling.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg